An extended interval between vaccination and i... - CLL Support

CLL Support

23,339 members40,047 posts

An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants

bennevisplace profile image
3 Replies

A newly published study insight.jci.org/articles/vi... takes a close look at the temporal aspects of hybrid immunity - i.e. humoral immunity after both SARS-CoV-2 infection and vaccination - in 96 health care workers.

"We find robust neutralizing antibody responses among those with hybrid immunity against all variants, including Omicron BA.2, and significantly improved neutralizing titers with longer vaccine-infection intervals up to 400 days. These results indicate that anti-SARS-CoV-2 antibody responses undergo continual maturation following primary exposure by either vaccination or infection for at least 400 days after last antigen exposure. We show that neutralizing antibody responses improved upon secondary boosting with greater potency seen after extended intervals. Our findings may also extend to booster vaccine doses, a critical consideration in future vaccine campaign strategies".

As we move from Covid pandemic to Covid endemic, with an increasing percentage of the population having been infected at least once and vaccinated several times, hybrid immunity is becoming the norm. This new study prompts a re-think of existing vaccination policy, based on earlier research into the durability of vaccine effectiveness e.g. thelancet.com/journals/lanc...

Written by
bennevisplace profile image
bennevisplace
To view profiles and participate in discussions please or .
Read more about...
3 Replies
bennevisplace profile image
bennevisplace

A question many of us would like answered. Without the data we don't know - we can assume the subjects of this study all to have normal immune responses. It would be interesting to see the equivalent study in a fairly homogeneous set of immunocompromised patients. Maybe LLS has relevant data?

I doubt that such a study would debunk the existing policy of vaccinating immunocompromised folk more frequently than the majority of the population.

AussieNeil profile image
AussieNeilPartnerAdministrator in reply tobennevisplace

"I doubt that such a study would debunk the existing policy of vaccinating immunocompromised folk more frequently than the majority of the population."

Given the LSS and UK studies found that we could sometimes respond and make antibodies after additional jabs, I expect that it's research into the timing for booster jabs for us which is needed. Remember the recommendation by some CLL specialists for flu vaccinations twice a year?

Neil

bennevisplace profile image
bennevisplace in reply toAussieNeil

You're probably right, in that a hybrid immunity study would be less helpful for immunocompromised folk than for the rest of the population, while the booster interval would seem to be more relevant. Didn't someone recently mention this phase 3 trial? clinicaltrials.gov/ct2/show...

A vaccine designed to turbocharge the cellular immune response might help too. Again, I seem to recall there was a recent post? It all gets a bit hazy these days...

Not what you're looking for?

You may also like...

Research shows blood cancer patients generate strong T cell immunity after SARS-CoV-2 vaccination

Today, the Doherty Institute in Melbourne, Australia, released a statement about a research study...
CLLerinOz profile image
Administrator

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T

We evaluated 254 COVID-19 patients longitudinally from early infection and for eight months...
zaax profile image

Dr. John Byrd: Monitoring Vaccination Effectiveness for Preventing SARS-CoV-2 Infection & COVID-19 Syndrome in CLL

CLL Society's new Opinion Page: Dr. John Byrd on Monitoring Vaccination Effectiveness for...
bkoffman profile image
CLL CURE Hero

Important SARS-CoV-2 and Covid-19 information for Chronic Lymphocytic Leukaemia/CLL patients

This post, prepared in collaboration with        @[52122] , draws together some earlier posts...
CLLerinOz profile image
Administrator

Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab

For more than a year we have been reminding each other that even if we don't produce antibodies in...